According to a recent LinkedIn post from Nuevocor, the company is bringing on Dr. Monica Ravindra Shah, MD, FACC as its chief medical officer. The post highlights that Shah is a board-certified heart failure and transplant cardiologist joining as the company prepares to initiate a first-in-human clinical trial of NVC-001 in LMNA-associated dilated cardiomyopathy.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The post notes that Shah has more than two decades of experience in cardiovascular medicine and drug development, including prior roles as CMO at CTI Clinical Trial & Consulting and in cardiovascular gene therapy at Rocket Pharmaceuticals. For investors, this senior hire suggests Nuevocor is moving closer to a key clinical inflection point, potentially enhancing its execution capabilities and credibility in the competitive genetic cardiomyopathy and gene therapy landscape.